PDL-HM410B-100μg / 询价
PDL-HM410B-500μg / 询价
PDL-HM410B-500μgx2 / 询价
Biotinylated Human PD-L1/B7-H1 Protein
Recombinant Biotinylated Human PD-L1/B7-H1 is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe19-Arg238 [Accession | Q9NZQ7-1].
The protein has a predicted MW of 28.1 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human PD-L1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human PD-L1 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human PD-L1, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human PD-1, hFc Tag with the EC50 of 5.2ng/ml determined by ELISA (QC Test).
Immobilized Anti-PD-L1 Antibody, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Human PD-L1, His Tag with the EC50 of 9.4ng/ml determined by ELISA.
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance.
CD274; PDL1; PD-L1; PD-L1B7 homolog 1;B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1
(1)Blank C , Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion[J]. Cancer Immunology Immunotherapy, 2007, 56(5):739-745.
